Spyre Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SYRE Nasdaq 2830 www.spyre.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Spyre Therapeutics, Inc.

This Stock’s Already Up Nearly 600% Over the Past Year - Aug 19th, 2026 9:45 am
Can Spyre Therapeutics (SYRE) Justify Its Premium After Positive Phase 2 Data? - Aug 9th, 2026 9:20 pm
Spyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know - Aug 6th, 2026 5:37 pm
A Spyre Executive Sold Stock After a 500% Run. Here's What Long-Term Investors Should Know - Aug 6th, 2026 5:30 pm
SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses - Aug 5th, 2026 9:08 am
Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Aug 4th, 2026 2:02 pm
Spyre Therapeutics Announces Grants of Inducement Awards - Jul 2nd, 2026 2:05 pm
Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts - Jun 29th, 2026 9:16 am
Spyre Therapeutics Shares Slide Following Large Insider Stock Sales (SYRE) - Jun 24th, 2026 6:53 am
cAMPfield lands $180M to build gut disease drug - Jun 18th, 2026 5:45 am
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients - Jun 15th, 2026 6:00 am
SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up - Jun 4th, 2026 8:56 am
Spyre Therapeutics (SYRE): 12 Best High Short Interest Stocks With Highest Upside Potential - Jun 4th, 2026 3:07 am
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA - Jun 3rd, 2026 6:00 am
Why Spyre Therapeutics (SYRE) Is Down 6.1% After Broadening Its SPY003 Paragon License Terms - Jun 2nd, 2026 4:07 pm
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares - May 17th, 2026 1:13 pm